Healthcare / BiotechnologyKSE
$7140.00
+610.00 (+9.34%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 17%
FCF escenarios
weak_data · normalized FCF $-98.9B · quality 39.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
27/100
D
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$429.1B
P/E
19.3x
↓EV/EBITDA
13.8x
↑ROE
5.4%
↑Gross Margin
-88.2%
↓Debt/Equity
0.35
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
-690.4%
FCF / Net income
-4.44x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $14.33B · net income $22.30B · FCF $-98.90B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $14.33B | $14.33B | $689.1M | $161.8M | — |
| Net Income | $22.30B | $22.30B | $-32.92B | $17.57B | $-211.45B |
| EBITDA | $33.35B | $33.35B | $-31.02B | $10.51B | $-206.76B |
| EPS | 370.20 | 370.20 | -549.00 | 293.60 | -3519.20 |
| Gross Margin | -88.2% | -88.2% | -1583.6% | 100.0% | — |
| Operating Margin | -470.1% | -470.1% | -9106.4% | 659.4% | — |
| Net Margin | 155.6% | 155.6% | -4777.6% | 10855.9% | — |
| Balance Sheet | |||||
| Debt/Equity | 0.35 | 0.35 | 0.20 | 0.19 | 0.01 |
| Current Ratio | 1.03 | 1.03 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-98.90B | $-98.90B | $-76.02B | $-125.89B | $-114.02B |
| Returns | |||||
| ROE | 5.4% | 5.4% | -7.5% | 3.9% | -49.2% |
| Valuation | |||||
| P/E | 19.29 | 19.29 | — | 30.25 | — |
| EV/EBITDA | 13.76 | 13.76 | — | 46.71 | — |
| P/B | 1.05 | 1.05 | 1.26 | 1.18 | 1.64 |
| Growth & Yield | |||||
| Revenue Growth | 1979.0% | 1979.0% | 325.8% | — | — |
| EPS Growth | 167.4% | 167.4% | -287.0% | 108.3% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
19.6%
EPS terminal req.
$633.56
Spread vs growth
147.8%
5Y implied EPS CAGR
15.7%
EPS terminal req.
$766.60
Spread vs growth
151.8%
10Y implied EPS CAGR
12.8%
EPS terminal req.
$1234.62
Spread vs growth
154.6%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-45.4%
Start / end P/E
n/dx → n/dx
EPS bridge
-549.00 → 370.20
Residual
-45.4%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.